Patient Preferences for Systemic Atopic Dermatitis Treatments in the UK, France and Spain: A Discrete Choice Experiment
Author(s)
Thomas C1, Raibouaa A2, Wollenberg A3, Capron JP4, Krucien N1, Karn H1, Tervonen T1
1Evidera, London, UK, 2Eli Lilly, Windlesham, UK, 3Department of Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany, 4Eli Lilly, Brussels, Belgium
OBJECTIVES: This study quantified preferences of adults with Atopic Dermatitis (AD) for efficacy, safety, and convenience treatment features. METHODS: Patients in UK, France, and Spain with systemic or topical treatment experience within the past 2 years completed a discrete choice experiment. Preferences for attributes were analyzed using a multinomial logit model. Willingness to make trade-offs was expressed as the maximum acceptable decrease (MAD) in the probability of achieving clear or almost clear skin at week 16 (IGA score of 0 or 1). RESULTS: The survey was completed by 404 patients (44.1±12.0 years of age; 65% female; 48% moderate AD (POEM score 8-16); 68% naïve to self-injectable treatments). The most common current treatments were betamethasone (29%) and hydrocortisone (28%). Participants most valued treatment benefits and reduced risks (in descending order: increasing the chance of achieving a meaningful reduction in itch (NRS reduction ≥4) at week 16 from 20% to 50%, reducing the risk of serious infections from 6% to 0%, reducing the risk of eye inflammation from 20% to 0%, and increasing the chance of achieving clear or almost clear skin at week 16 from 10% to 40%). However, they would be willing to accept a decrease in the possibility of achieving clear or almost clear skin for the following trade-offs: a treatment that can be paused over one that cannot (MAD = 24.1% [95% CI, 16.5%–31.6]); a once-daily oral pill over a subcutaneous injection every 2 weeks (MAD = 16.6% [95% CI, 9.2%–24.0%]); and a 2-day over a 2-week onset of action (MAD = 11.3% [95% CI, 4.4%–18.2%]). CONCLUSIONS: Although patients with AD most valued treatment benefits and reducing risks, they were willing to tolerate reduced efficacy in exchange for non-clinical attributes such as oral administration, the possibility for treatment pauses, and a rapid onset.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PMU105
Topic
Patient-Centered Research
Topic Subcategory
Stated Preference & Patient Satisfaction
Disease
Sensory System Disorders, Systemic Disorders/Conditions